Combining local ablative therapy with ongoing systemic treatment for certain cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 pragmatic study evaluates the benefits of continuing systemic therapy while adding locally ablative therapies for patients with oligo-progressive solid tumors. The primary goal is to measure the time to treatment failure after receiving local ablative therapy, with disease control assessed at three months. Participants will receive either stereotactic ablative radiotherapy or interventional radiology ablation therapy, depending on the treating physician's discretion. The study will follow participants for up to five years to monitor outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies:

   1. Cohort A: Breast Malignancy
   2. Cohort B: Gynecological Malignancy
   3. Cohort C: Head and Neck Malignancies
   4. Cohort D: Sarcomas
   5. Cohort E: Other solid malignancy specified in the protocol
2. Provision of signed and dated informed consent form.
3. Stated willingness to comply with all study procedures and availability for the duration of the study.
4. Age ≥18 years at time of consent.
5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.
6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\]
7. ≤ 5 progressing or new metastatic lesions.
8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.

Exclusion Criteria:

1. Medical comorbidities precluding locally ablative therapies.
2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.
3. Progressing intracranial lesions.

Where it's running

• University of California, Davis
  Sacramento, California, United States Recruiting

Study contacts

• Principal investigator: Xiao Zhao, MD — University of California, Davis
• Study coordinator: Office of Clinical Research
• Email: OCRReferral@health.ucdavis.edu
• Phone: 916-382-6970

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• Combination therapy using checkpoint inhibitors for advanced solid tumors

  This study is testing a new combination treatment using special antibodies for people with advanced solid tumors like lung and liver cancer to see if it can be safer and more effective than current options.

  Recruiting Phase 1/2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05187338

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.